EVOTEC INDIGO
LIVE

Serial Number

79304082

Owner

Evotec International GmbH

Attorney

William E OBrien, Esq.

Filing Date

Dec 21, 2020

Add to watchlist:

No watchlists yet
View on USPTO

EVOTEC INDIGO Trademark

Serial Number: 79304082 • Registration: 6733704

EVOTEC INDIGO is a trademark filed by Evotec International GmbH on December 21, 2020. The trademark is classified under Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Evotec International GmbH (4 trademarks)

Hamburg 22419 , DE

Entity Type: 99

Trademark Details

Filing Date

December 21, 2020

Registration Date

May 24, 2022

Published for Opposition

March 8, 2022

Goods & Services

Consultation in the field of regulatory compliance with respect to the pharmaceutical and medical products of others; regulatory compliance consulting services as they apply to clinical trials and preclinical drug development

Medical and scientific research in the fields of neuroscience, oncology, immunology and inflammation, metabolic diseases and complications, respiratory and anti-infective diseases, dermatology, haematology, ophthalmology, rare diseases; conducting clinical trials for others in the field of neuroscience, oncology, immunology and inflammation, metabolic diseases and complications, respiratory and anti-infective diseases, dermatology, haematology, ophthalmology, rare diseases,; clinical research in the field of neuroscience, oncology, immunology and inflammation, metabolic diseases and complications, respiratory and anti-infective diseases but also in many other indications in the fields of dermatology, haematology, ophthalmology, rare diseases; pharmaceutical research services; medical and scientific research consultation pertaining to pharmacology, toxicology, drug metabolism, pharmacokinetics, bioanalysis, and tablet compression; research of medicines; development of pharmaceutical preparations, formulations, drug substances, drug products, active pharmaceutical ingredients, and medicines; research to develop pharmaceutical products; design and testing of new pharmaceutical products for others

Pharmaceutical cost management services

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 6, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 17, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 8, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 8, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 24, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 24, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
May 24, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 8, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 8, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 16, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 16, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 16, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 1, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 31, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 31, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 31, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 31, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2022 TROA
REFUSAL PROCESSED BY IB
Aug 1, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 8, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jul 8, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 24, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jun 23, 2021 CNRT
ASSIGNED TO EXAMINER
Jun 16, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 16, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 11, 2021 REPR